Alger Jason 4

What Happened

• Jason Alger, Chief Financial Officer of Health Catalyst (HCAT), received equity awards on Feb 25, 2026: 507,500 restricted stock units (RSUs) and 22,222 performance-based restricted stock units (PRSUs) (total 529,722 units) granted at $0.00. On Feb 26, 2026 he had 7,522 shares sold at $1.75 each to satisfy tax withholding obligations, generating proceeds of $13,147. The grants are awards (code A) and the sale was a tax-withholding disposal (code F).

Key Details

• Transaction dates and prices:
  • 2026-02-25: Award of 507,500 RSUs (A) and 22,222 PRSUs (A) at $0.00.
  • 2026-02-26: 7,522 shares sold/withheld at $1.75 per share (F); proceeds $13,147.
• Vesting: RSUs vest in 12 equal quarterly installments beginning March 1, 2026 (per footnote). PRSUs are contingent on fiscal 2025 performance metrics.
• Sale reason: The 7,522-share sale was a mandatory "sell to cover" to satisfy tax withholding under the issuer’s equity plan (not a discretionary open-market sale).
• Shares owned after transaction: Not disclosed in the Form 4 filing.
• Filing timeliness: Form 4 was filed Feb 27, 2026 for transactions on Feb 25–26, 2026 — appears timely (no late filing indicated).

Context

• These awards are compensation-based grants (contingent rights to shares), not open-market purchases; they represent potential future share issuance as they vest.
• The small sale was solely for tax withholding under the company’s plan and should not be interpreted as a voluntary sell signal from the CFO.
• For retail investors, equity awards increase potential future share dilution as they vest; the immediate “sell to cover” was administrative, not an indicator of sentiment.